Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus abiraterone acetate and prednisone in first-line metastatic castration-resistant prostate cancer
CTR20212376Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Started Sep 2021; status: terminated.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20212376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212376.